Hepatic Cirrhosis Clinical Trial
Official title:
Hyperproteic and Fiber-rich Diet Plus Probiotics (Lactobacillus Reuteri) and Nitazoxanide in the Treatment of Minimal Hepatic Encephalopathy.
Hepatic encephalopathy is a serious complication of cirrhosis which relays under the burden of diseases with therapeutical difficulties for its given morbidity and mortality and the high recurrence it poses. Its treatment remains a challenge for most of the cases. Even more, minimal hepatic encephalopathy is an entity that has an additional morbidity for it being a subclinical entity. As so, the investigators propose an auxiliary treatment for the management of such patients with minimal hepatic encephalopathy, using a specific diet consisting on hyperproteic and fibre-rich foods along with two independent interventions, whether a probiotic, lactobacillus reuteri, or a drug, nitozoxanide, so to diminish the rate of progression to any clinical stage of hepatic encephalopathy and to revert minimal hepatic encephalopathy itself to none hepatic encephalopathy.
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
| Completed |
NCT02138253 -
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
|
Phase 2 | |
| Recruiting |
NCT02652351 -
Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
|
Phase 1 | |
| Completed |
NCT00794482 -
Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
|
Phase 3 | |
| Completed |
NCT00856713 -
Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02163512 -
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
|
||
| Completed |
NCT00857480 -
Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
|
Phase 1 | |
| Completed |
NCT00006164 -
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
|
Phase 3 | |
| Completed |
NCT03486912 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
|
Phase 2 | |
| Completed |
NCT00698464 -
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
|
Phase 1 | |
| Completed |
NCT02778425 -
The Treatment of Hepatocirrhosis and Portal Hypertension
|
N/A | |
| Completed |
NCT03445208 -
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
|
Phase 1 | |
| Completed |
NCT03420768 -
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
|
Phase 2 | |
| Completed |
NCT03804593 -
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
|
||
| Completed |
NCT03712280 -
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
|
Phase 2 | |
| Completed |
NCT02230670 -
A Study of IDN-6556 in Subjects With Liver Cirrhosis
|
Phase 2 | |
| Completed |
NCT02230683 -
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
|
Phase 2 | |
| Completed |
NCT00856869 -
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
|
Phase 1/Phase 2 |